The Anti-Phospholipid Antibody (APL) IgA test detects IgA autoantibodies against phospholipids, which are important for normal blood clotting. While IgG and IgM are more commonly tested, IgA APL antibodies may be useful in specific cases, such as patients with antiphospholipid syndrome (APS) who are negative for IgG and IgM but still have symptoms of clotting disorders or pregnancy complications.
✅ Diagnose Antiphospholipid Syndrome (APS) in seronegative cases (IgG/IgM negative but symptoms present)
✅ Evaluate unexplained blood clots (DVT, stroke, pulmonary embolism)
✅ Assess risk of recurrent pregnancy loss, preeclampsia, or fetal growth restriction
✅ Monitor autoimmune diseases (e.g., systemic lupus erythematosus – SLE)
| Result | Interpretation |
|---|---|
| Negative | No significant Anti-Phospholipid IgA antibodies detected |
| Low Positive | May be incidental, consider repeat testing |
| Moderate to High Positive | Possible APS or increased clotting risk, especially if persistent |
🔹 IgA APL antibodies are less commonly tested but may be relevant in seronegative APS cases.
🔹 Persistence for ≥ 12 weeks is required to confirm APS diagnosis.
Primary Antiphospholipid Syndrome (APS) → Increased risk of blood clots and pregnancy complications.
Secondary APS → Occurs with systemic lupus erythematosus (SLE), rheumatoid arthritis, or Sjögren’s syndrome.
Unexplained Blood Clots → May include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
Pregnancy Complications → Can lead to miscarriages, stillbirth, preeclampsia, or fetal growth restriction.
Autoimmune Disorders → IgA APL antibodies may be present in SLE, inflammatory diseases, and chronic infections.
✔ Anti-Phospholipid IgG & IgM Antibodies → IgG is most strongly associated with APS.
✔ Lupus Anticoagulant (LA) Test → Strong predictor of clotting risk.
✔ Anti-Cardiolipin Antibodies (IgG, IgM, IgA) → Common in APS.
✔ Beta-2 Glycoprotein I Antibodies (IgG, IgM, IgA) → Highly specific for APS.
✔ Coagulation Tests (PT, aPTT, dRVVT) → Identify clotting abnormalities.
🔹 Repeat testing after 12 weeks to confirm persistence.
🔹 Check for history of thrombosis (DVT, PE, stroke) and pregnancy complications.
🔹 Consider testing for IgG and IgM APL antibodies if not already done.
🔹 Referral to a rheumatologist or hematologist for APS evaluation if clotting risk is high.
🔹 Anticoagulation therapy (warfarin, heparin, aspirin) may be needed in high-risk patients.